The ABI1 (Abelson Interactor 1) antibody is a tool used to detect the ABI1 protein, a key regulator of cytoskeletal dynamics and cellular signaling. ABI1. part of the WAVE regulatory complex (WRC), facilitates actin polymerization by linking upstream signals to the activation of the Arp2/3 complex. It contains modular domains, including an SH3 domain that interacts with proline-rich motifs in partners like Abelson tyrosine kinase (c-Abl), and plays roles in cell migration, proliferation, and endocytosis. Dysregulation of ABI1 is implicated in cancer progression, neurodegenerative disorders, and immune dysfunction. For instance, reduced ABI1 expression correlates with enhanced tumor invasiveness in breast and lung cancers, while mutations may disrupt synaptic function in Alzheimer's disease. The ABI1 antibody is widely utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its expression, localization, and post-translational modifications (e.g., phosphorylation at Y421). Researchers also employ it to explore ABI1's interactions with pathways such as EGFR/Ras-MAPK and its tumor-suppressive or context-dependent oncogenic roles. Its development and validation have advanced understanding of ABI1's dual functionality in health and disease, aiding therapeutic target discovery.